脂质体肺部给药的应用进展  

Application and Development of Liposome Formulation in Pulmonary Delivery

作　　者：汪燕[1] 汤玥[1] 鲁锡峰[1] 朱家壁[1] 

机构地区：[1]中国药科大学药学院药物制剂研究所,南京210009

出　　处：《药学与临床研究》2011年第3期253-256,共4页Pharmaceutical and Clinical Research

基　　金：中央高校基本科研业务费专项资金资助(项目批准号JKP2009009)

摘　　要：脂质体肺部给药作为一种非侵入性给药形式,可以使药物局部定量化,实现肺部疾病的直接靶向,免除肝脏首过效应,生物利用度高,同时通过脂质双层的延时作用,避免频繁给药。本文介绍了脂质体肺部给药的相关优越性、给药方式以及国内外有关脂质体作为抗炎抗感染药物、抗氧化药物、抗哮喘药物、抗肿瘤药物、抗血栓药物等的载体,通过肺部给药的形式发挥相关作用的研究与进展。The liposome-mediated pulmonary drug delivery as a non-invasive administration,makes drugs located at the site of action to treat pulmonary diseases directly,reduces extrapulmonary side-effects,avoids the hepatic first pass effect,increases the bioavailability and avoids frequent administration as the double-layer of the liposome can increase the retention-time.The related advantage of the liposome-mediated pulmonary drug delivery and the way of administration are mainly introduced in this review.We also summarized the research and development of the relevant liposomes at home and abroad,being used to work through pulmonary pathway,as the carriers of antiinflammatory and anti-infective drugs,antioxidants,antasthmatics,antitumor drugs,antithrombotics and so on.

关 键 词：脂质体 肺部给药 载体 雾化 吸入 安全性 

分 类 号：R974[医药卫生—药品] R943[医药卫生—药学]